The iron chelator desferrioxamine (DFO) B is widely used in the therapy of patients with iron overload. As a side effect, DFO may favor the occurrence of fulminant Yersinia infections. Previous work from our laboratory showed that this might be due to a dual role of DFO: growth promotion of the pathogen and immunosuppression of the host. In this study, we sought to determine whether conjugation of DFO to hydroxyethyl starch (HES-DFO) may prevent exacerbation of Yersinia infection in mice. We found HES-DFO to promote neither growth of Yersinia enterocolitica nor mitogen-induced T-cell proliferation and gamma interferon production by T cells in vitro. Nevertheless, in vivo HES-DFO promoted growth of Y. enterocolitica possibly due to cleavage of HES and release of DFO. The pretreatment of mice with DFO resulted in death of all mice 2 to 5 days after application of a normally sublethal inoculum of Y. enterocolitica, while none of the mice pretreated with HES-DFO died within the first 7 days postinfection. However, some of the HES-DFO-treated mice died 8 to 14 days postinfection. Thus, due to the delayed in vivo effect HES-DFO failed to trigger Yersinia-induced septic shock, which accounts for early mortality in DFO-associated septicemia. Moreover, our data suggest that DFO needs to be taken up by host cells in order to exert its immunosuppressive action. These results strongly suggest that HES-DFO might be a favorable drug with fewer side effects than DFO in terms of DFO-promoted fulminant infections.Yersinia enterocolitica is a gram-negative bacterium which is pathogenic for humans and rodents (23,25). Infection with this pathogen causes a wide range of clinical manifestations including enterocolitis and mesenteric lymphadenitis (28). In immunocompromised patients or patients with iron overload, Yersinia causes systemic infections with abscesses in spleen and liver (27,33,37).Previous work from this laboratory showed that desferrioxamine (DFO) may play a dual role in pathogenesis of Yersinia infection: growth and virulence promotion of Y. enterocolitica by iron provision to the pathogen and immunosuppression of the host. In fact, iron-loaded DFO (ferrioxamine [FO]) can be taken up and used as an iron source by Yersinia (16, 36). The genes encoding FO uptake have been characterized and are considered part of the virulence factors required for high-level pathogenicity of Yersinia (10, 11).On the other hand, DFO exerts effects on various components of the immune system of the host. DFO inhibits proliferation of T and B lymphocytes and cytokine production of macrophages and modulates interaction of polymorphonuclear leukocytes with yersiniae (3, 21). In keeping with these observations, we and others have demonstrated that DFO increases pathogenicity of Y. enterocolitica in mice, resulting in fatal septicemia and shock (5, 39, 40). Moreover, fatal septicemia with Yersinia and other microorganisms including the fungus Rhizopus sp. has been reported for patients undergoing DFO therapy (13,15,40).In an attempt to find drug...